论文部分内容阅读
目的:观察并探讨通过芪凌方联合岩舒注射液治疗晚期前列腺癌(Advanced prostate cancer,APC)的临床疗效。方法:APC患者150例,完全随机分为观察组与对照组各75例。对照组患者既往给予双侧睾丸切除(手术去势)加全雄激素阻断治疗,观察组患者为对照组患者的治疗基础上另予芪凌方联合岩舒注射液治疗。记录两组患者治疗前后的前列腺特异抗原(prostate specific antigen,PSA),KPS评分,最大尿流速及前列腺体积,统计其治疗后的并发症发生情况以及总体疗效。结果:除两组患者的前列腺体积大小无明显差异(P>0.05),观察组的各项观察指标均优于对照组(P<0.05)。结论:芪凌方联合岩舒注射液治疗可以改善APC患者病情,提高患者生存质量,在临床上值得推广应用。
Objective: To observe and discuss the clinical efficacy of Qi Lingfang combined with Yan Shu injection in the treatment of advanced prostate cancer (APC). Methods: 150 APC patients were randomly divided into observation group and control group, 75 cases in each. Patients in the control group were treated by bilateral orchiectomy (surgical castration) plus androgen and blockade therapy. Patients in the observation group were treated with Qilingfang combined with Yanshu injection on the basis of the treatment of patients in the control group. The prostate specific antigen (PSA), KPS score, maximal urinary flow rate and prostate volume before and after treatment were recorded before and after treatment. The incidence of complications after treatment and the overall efficacy were recorded. Results: There was no significant difference in the size of prostate between the two groups (P> 0.05). All the observation indexes in the observation group were better than those in the control group (P <0.05). Conclusion: Qiling prescription combined with Yan Shu injection can improve the condition of patients with APC and improve the quality of life of patients, which is worthy of popularization and application in clinic.